China Resources Double Crane: DC7001A Capsule Obtains Notification of Clinical Trial Approval

China Resources Double Crane announced that its wholly-owned subsidiary Beijing Double Crane Run-Chuang Technology Co., Ltd. has received the Clinical Trial Approval Notice for the DC7001A capsule issued by the National Medical Products Administration, granting permission to conduct clinical trials. This drug is classified as a first-class chemical drug and is intended for the treatment of systemic lupus erythematosus and cutaneous lupus erythematosus. As of the announcement date, the total amounts to RMB 15,709,700.